[go: up one dir, main page]

MX2007010930A - Formulacion de aviptadil. - Google Patents

Formulacion de aviptadil.

Info

Publication number
MX2007010930A
MX2007010930A MX2007010930A MX2007010930A MX2007010930A MX 2007010930 A MX2007010930 A MX 2007010930A MX 2007010930 A MX2007010930 A MX 2007010930A MX 2007010930 A MX2007010930 A MX 2007010930A MX 2007010930 A MX2007010930 A MX 2007010930A
Authority
MX
Mexico
Prior art keywords
aviptadil
formulation
derivatives
buffer
stability
Prior art date
Application number
MX2007010930A
Other languages
English (en)
Inventor
Gerald Bacher
Dorian Bevec
Original Assignee
Mondobiotech Licensing Out Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Licensing Out Ag filed Critical Mondobiotech Licensing Out Ag
Publication of MX2007010930A publication Critical patent/MX2007010930A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invencion se refiere a formulaciones farmaceuticas de Aviptadil y sus derivados. Se comprobo que la estabilidad de la formulacion de Aviptadil se mejora mediante una formulacion que tiene una concentracion de Aviptadil definida preparada en un tampon que tiene un rango de pH definido.
MX2007010930A 2005-03-07 2006-03-07 Formulacion de aviptadil. MX2007010930A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005010415 2005-03-07
US66282105P 2005-03-18 2005-03-18
PCT/EP2006/002084 WO2006094764A1 (en) 2005-03-07 2006-03-07 Formulation for aviptadil

Publications (1)

Publication Number Publication Date
MX2007010930A true MX2007010930A (es) 2008-03-14

Family

ID=36354043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010930A MX2007010930A (es) 2005-03-07 2006-03-07 Formulacion de aviptadil.

Country Status (10)

Country Link
US (1) US8178489B2 (es)
EP (1) EP1855661B1 (es)
JP (1) JP2008537542A (es)
AU (1) AU2006222233B2 (es)
CA (1) CA2601279A1 (es)
ES (1) ES2363738T3 (es)
MX (1) MX2007010930A (es)
NZ (1) NZ560648A (es)
PL (1) PL1855661T3 (es)
WO (1) WO2006094764A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2009033746A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
ES2531657T3 (es) * 2008-05-01 2015-03-18 Arecor Limited Formulación de una proteína
US20120018338A1 (en) * 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
CN103159845B (zh) * 2013-03-26 2015-03-18 深圳翰宇药业股份有限公司 一种合成阿肽地尔的方法
CN104447963B (zh) * 2014-11-14 2017-11-07 杭州阿诺生物医药科技股份有限公司 一种制备阿肽地尔的方法
JP7523834B2 (ja) * 2020-12-04 2024-07-29 センチュリオン イラック サナイ ヴェ ティカレット アノニム シルケティ 吸入型血管作動性腸ポリペプチドの新しい投与計画
TR2022010940A2 (tr) * 2022-07-01 2024-01-22 Centuri̇on İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Avi̇ptadi̇l sivi formülasyon üreti̇m yöntemi̇.
CN120152699A (zh) * 2022-11-02 2025-06-13 瑞利福制药国际股份有限公司 稳定的阿肽地尔制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898329A (en) 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
US4016258A (en) 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4237046A (en) * 1979-04-27 1980-12-02 Miklos Bodanszky Polypeptides and methods of preparation
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
ES2063406T3 (es) * 1990-06-26 1995-01-01 Sanwa Kagaku Kenkyusho Co Procedimiento para la preparacion de analogos de polipeptido intestinal vasoactivo.
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
US5681816A (en) * 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
JP2004500906A (ja) 1999-11-12 2004-01-15 ルーベン，　レオ 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
KR20040065212A (ko) * 2001-11-06 2004-07-21 센주 세이야꾸 가부시키가이샤 건조안 및 건조안과 연관된 질환의 치료제
AU2003284428B2 (en) 2002-11-27 2010-08-26 Ils Inc. Peptides and medicinal compositions containing the same

Also Published As

Publication number Publication date
JP2008537542A (ja) 2008-09-18
US20080161237A1 (en) 2008-07-03
EP1855661A1 (en) 2007-11-21
AU2006222233B2 (en) 2011-05-12
EP1855661B1 (en) 2011-05-04
NZ560648A (en) 2010-03-26
ES2363738T3 (es) 2011-08-12
US8178489B2 (en) 2012-05-15
CA2601279A1 (en) 2006-09-14
AU2006222233A1 (en) 2006-09-14
WO2006094764A1 (en) 2006-09-14
PL1855661T3 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
IL272236A (en) Preparations and methods for preparing drugs that are hardly soluble in water with increased stability
WO2008128049A3 (en) Tetrahydrobiopterin compositions and methods of measuring
UA94052C2 (uk) Похідні піридазину
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MY159156A (en) Antibody formulation
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
IL198687A0 (en) Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
JO2852B1 (en) Anti-cancer compounds and pharmaceutical compositions
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
UA96994C2 (ru) Производные 7-алкинил-1,8-нафтиридонов, способ их получения и их применения в терапии
TW200616976A (en) Pyrimidine derivatives
MX2009003169A (es) Derivados de sulfonamida.
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
MX2007010930A (es) Formulacion de aviptadil.
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
GEP20105031B (en) Stable emulsion composition
WO2007038627A3 (en) Stabilized antimicrobial compositions and related methods of preparation
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MX2010010017A (es) Derivados de guanidina lineales y ciclicos, metodo de preparacion y sus usos.
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
NO20065791L (no) Asyklovir-formuleringer

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration